GlassScriptPhysician profile
Kavya Desai
NPI 1093370074
$5,428.42
in general payments reported to CMS, 2019-2025
21 companies · $3,067 in 2025
The $3,067 reported for 2025 was more than what 85% of Dermatology providers received nationally (typical 2025 total: $772).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2022: $221 · 2023: $978 · 2024: $1,163 · 2025: $3,067.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $4,243 · Travel and Lodging: $851 · Education: $114.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $4,242.95 |
| Travel and Lodging | $851.08 |
| Education | $113.53 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $1,417.58 | 2022-2025 | Natrelle Saline-Filled Breast Implants, Revolve |
| Janssen Biotech, INC. | $920.13 | 2024-2025 | Tremfya |
| Pfizer INC. | $594.76 | 2024-2025 | |
| Galderma Laboratories, L.P. | $389.79 | 2025 | Nemluvio, Aklief |
| Leo Pharma INC. | $350.55 | 2024-2025 | Adbry, Anzupgo |
| Regeneron Healthcare Solutions, INC. | $309.37 | 2024-2025 | Dupixent |
| Incyte Corporation | $298.59 | 2024-2025 | Opzelura |
| Ucb, INC. | $253.22 | 2024-2025 | Bimzelx |
| Genzyme Corporation | $201.62 | 2024 | |
| Lilly USA, LLC | $172.98 | 2024-2025 | Taltz, Ebglyss |
| Allergan, INC. | $112.15 | 2022 | |
| Novartis Pharmaceuticals Corporation | $88.76 | 2024-2025 | |
| E.R. Squibb & Sons, L.L.C. | $83.52 | 2022-2024 | Sotyktu |
| Botanix Sb INC | $67.39 | 2025 | Sofdra |
| Boehringer Ingelheim Pharmaceuticals, INC. | $48.49 | 2024-2025 | Spevigo |
Show all 21 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Organon LLC | $30.09 | 2025 | |
| Chiesi USA, INC. | $22.51 | 2025 | Filsuvez |
| Medimetriks Pharmaceuticals, INC. | $19.42 | 2025 | |
| Sun Pharmaceutical Industries INC. | $19.01 | 2025 | |
| Almirall LLC | $14.41 | 2024 | Klisyri |
| Arcutis Biotherapeutics, INC. | $14.08 | 2024 | Zoryve |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Kavya Desai listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.